ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

Zhang, Fengchun; Zheng, Jie; Li, Yang; Wang, Guochun; Wang, Mingjun; Su, Yin; Gu, Jieruo; Li, Xingfu; Bass, Damon; Chu, Myron; Curtis, Paula; DeRose, Kathleen*; Kurrasch, Regina; Lowe, Jenny; Meizlik, Paige; Roth, David A.北京大学; 山东大学; 上海交通大学; 哈尔滨医科大学; 苏州大学; 中国医学科学院; 中山大学; 中国医学科学院北京协和医院; 1
RMD Open2022-4DOI: 10.1136/rmdopen-2021-001669
4被引8阅读
引用收藏
分享

摘要

Objectives To evaluate the long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) in China. Methods In this phase 3, open-label extension period, eligible completers of study BEL113750 (NCT01345253) received intravenous belimumab 10 mg/kg monthly for <= 6 years. The primary endpoint was safety. Secondary endpoints included the SLE Responder Index (SRI)-4 response rate, severe SLE flares and changes in prednisone use. Analyses were based on observed data from the first dose of belimumab through to study end. Results Of the 424 patients who received belimumab, 215 (50.7%) completed the study, 208 (49.1%) withdrew and 1 patient died. Overall, 359/424 (84.7%) patients had adverse events (AEs), and 96/424 (22.6%) had serious AEs. 26/424 (6.1%) patients discontinued study treatment/withdrew from the study due to AEs. Postinfusion systemic reaction rate was 1.5 events/100 patient-years. Herpes zoster infection rate was 3.0 events/100 patient-years, of which 0.4 events/100 patient-years were serious events. One papillary thyroid cancer and one vaginal cancer were reported in year 0-1 and year 3-4, respectively. There were no completed suicides/suicide attempts and no reports of serious depression. The proportion of SRI-4 responders increased progressively (year 1, week 24: 190/346 (54.9%); year 5, week 48: 66/82 (80.5%)). Severe flares were experienced by 55/396 (13.9%) patients. For 335 patients with baseline prednisone-equivalent dose >7.5 mg/day, the number of patients with a dose reduction to <= 7.5 mg/day increased over time (year 1, week 24: 30/333 (9.0%); year 5, week 48: 36/67 (53.7%)). Conclusions Favourable safety profile and disease control appeared to be maintained in patients with SLE in China for <= 6 years, consistent with previous belimumab studies.

学科与关键词

关键词
biological therapyB-lymphocytescytokineslupus erythematosussystemic
相关
加载中…
  • Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses
    Zheng, Jie; Gu, Jieruo; Su, Yin; Li, Yang; Li, Xingfu; Xiong, Cui; Cao, Hua; Quasny, Holly; Chu, Myron; Curtis, Paula; DeRose, Kathleen; Kurrasch, Regina; Meizlik, Paige; Roth, David A.; Zhang, Fengchun*Modern Rheumatology, 2023, 33(4): 751-757.被引 2
  • Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study
    Zhang, Shuoyang; Qiu, Qian; Zeng, Shan; Li, Hao; Xu, Liujing; Jie, Ligang; Hu, Xuejun; Xiao, Youjun; Chen, Dongying; Zhan, Zhongping; Liang, Liuqin*; Yu, Qinghong*; Xu, Hanshi*CLINICAL RHEUMATOLOGY, 2023.
  • Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy
    Liu, Diankun; Zhou, Qiang; Wang, Di; Qu, Yuan; Guo, Qihong; Wen, Jing; Yu, Qinghong*; Ai, Jun*Lupus, 2022, 31(12): 1456-1467.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
RMD Open
发表日期
2022-04
卷期
第 8 卷, 第 1 期
页码
e001669
DOI
10.1136/rmdopen-2021-001669
期刊等级
2区
成果收录
SCIE
资助标注
GlaxoSmithKline; GSK

作者

  • Z

    Zhang, Fengchun (第一作者)

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • Z

    Zheng, Jie

    ruijin hosp · shanghai jiao tong univ

查看全部 16 位作者收起作者
  • L

    Li, Yang

    2 · harbin med univ

  • W

    Wang, Guochun

    china japan friendship hosp

  • W

    Wang, Mingjun

    1 · soochow univ

  • S

    Su, Yin

    peking univ

  • G

    Gu, Jieruo

    sun yat sen univ

  • L

    Li, Xingfu

    shandong univ

  • B

    Bass, Damon

  • C

    Chu, Myron

  • C

    Curtis, Paula

  • D

    DeRose, Kathleen (通讯)

  • K

    Kurrasch, Regina

  • L

    Lowe, Jenny

  • M

    Meizlik, Paige

  • R

    Roth, David A.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417